Clinical Trial Detail

NCT ID NCT01806571
Title Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin

Nilotinib

Age Groups: adult

No variant requirements are available.